Search

US12605454B2 - Modified CMV VLPs as Vaccine Platform

USPTO granted Patent US12605454B2 to SAIBA AG for modified Cucumber Mosaic Virus (CMV) virus-like particles (VLPs) incorporating Th cell epitopes for enhanced immune responses as a vaccine platform. The 23-claim patent covers linking antigens to modified CMV VLPs to generate antibody responses. CPC classifications span infectious diseases, autoimmune conditions, metabolic disorders, and neurological applications. The patent application (17714307) was filed April 6, 2022.